Breaking News, Collaborations & Alliances

SAB Biotherapeutics Enters Exclusive Manufacturing Services Agreement with BioSolutions Inc.

Emergent will provide contract development and manufacturing (CDMO) services to produce SAB’s fully-human polyclonal antibody products.

Author Image

By: Charlie Sternberg

Associate Editor

SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, has entered into an exclusive manufacturing services agreement with Emergent BioSolutions Inc.   Emergent will provide contract development and manufacturing (CDMO) services to produce SAB’s fully-human polyclonal antibody products. Currently, SAB has clinical-stage programs in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters